WHAT IS CLAIMED IS:

1. An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, of the formula



optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.

2. The dosage form of claim 1 comprising 0.5-40 mg of said active ingredient.

3. The dosage form of claim 2 comprising 2-20 mg of said active ingredient.

4. The dosage form of claim 1 comprising 5-20% of said active ingredient (weight/volume).

5. The dosage form of claim 1 in a single-dose form.

6. The dosage form of claim 1 in the form of a solution or suspension.

7. The dosage form of claim 1 containing 15% of said active ingredient.

8. The dosage form of claim 1 wherein said excipient comprises a bioadhesive.

9. The dosage form of claim 1 wherein said excipient comprises a polymer that dissolves vehicle viscosity based on temperature change, to increase said viscosity at body temperature.

10. The dosage form of claim 1 further comprising as an excipient an intranasal absorption promoter.

11. The dosage form of claim 10 wherein said promoter is selected from the group consisting of POE (9) lauryl alcohol and sodium glycocholate and lysophosphatidyl choline.

12. A method for the treatment of inflammatory processes and pain of a traumatic or pathologic origin, which comprises the administration by the intranasal route of an effective amount of the active ingredient 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, in a racemic or optically active form or in the form of a pharmaceutically acceptable salt.

13. A method according to claim 8 wherein said effective amount is within the range of 0.5-40 mg.

14. A method according to claim 8 wherein said effective amount is within the range of 5-30 mg.

15. A method according to claim 8 wherein said effective amount is within the range of 5-20% (weight/volume).

16. A method according to claim 8 wherein said effective amount is within the range of 15% (weight/volume).

17. A method for the treatment of inflammatory processes and pain of a traumatic or pathologic origin which

comprises the administration by the intranasal route of a dosage form according to claim 1.

18. A method according to claim 17 wherein said mammal is a human and wherein said effective amount is sufficient to generate a plasma concentration of 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid within the range between 0.3 and 5 mg/liter of plasma.